These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25096190)

  • 1. Is a prospective trial necessary to suggest a clinical relevance?
    Pallud J; Duffau H
    Neuro Oncol; 2014 Sep; 16(9):1295-6. PubMed ID: 25096190
    [No Abstract]   [Full Text] [Related]  

  • 2. Does early identification of low-grade glioma growth impact outcome?
    Chamberlain MC
    Neuro Oncol; 2014 Sep; 16(9):1296. PubMed ID: 25125165
    [No Abstract]   [Full Text] [Related]  

  • 3. Textiloma resembling anaplastic progression of an isocitrate dehydrogenase 1 (IDH1) mutant, low grade glioma.
    Anderson MD; Raghunathan A; Gilbert MR
    J Neurooncol; 2013 Feb; 111(3):377-9. PubMed ID: 23203443
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular Pathogenesis of Low-Grade Glioma.
    Bready D; Placantonakis DG
    Neurosurg Clin N Am; 2019 Jan; 30(1):17-25. PubMed ID: 30470401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing diffuse glioma as a systemic brain disease with single-cell analysis.
    Sahm F; Capper D; Jeibmann A; Habel A; Paulus W; Troost D; von Deimling A
    Arch Neurol; 2012 Apr; 69(4):523-6. PubMed ID: 22158715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
    Singh A; Gurav M; Dhanavade S; Shetty O; Epari S
    Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On high-risk, low-grade glioma: What distinguishes high from low?
    Geurts M; van den Bent MJ
    Cancer; 2019 Jan; 125(2):174-176. PubMed ID: 30512190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular categorisation of gliomas.
    Burki TK
    Lancet Oncol; 2015 Jul; 16(7):e320. PubMed ID: 26095778
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?
    Mustafa DA; Swagemakers SM; Buise L; van der Spek PJ; Kros JM
    Acta Neuropathol Commun; 2014 Jan; 2():6. PubMed ID: 24405933
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
    Schiff D; Purow BW
    Nat Rev Neurol; 2009 Jun; 5(6):303-4. PubMed ID: 19498431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Response.
    Bhatia A; Moreno R; Reiner AS; Nandakumar S; Walch HS; Malani R; Panageas KS; Mellinghoff IK; Bale TA; Young RJ
    Clin Cancer Res; 2024 Feb; 30(3):639. PubMed ID: 38298142
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Letter.
    Mandonnet E
    Clin Cancer Res; 2024 Feb; 30(3):638. PubMed ID: 38298141
    [No Abstract]   [Full Text] [Related]  

  • 13. Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?
    Scott JG; Basanta D; Chinnaiyan P; Canoll P; Swanson KR; Anderson AR
    Neuro Oncol; 2011 Dec; 13(12):1262-4. PubMed ID: 21784755
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.
    Sun H; Yin L; Li S; Han S; Song G; Liu N; Yan C
    J Neurooncol; 2013 Jun; 113(2):277-84. PubMed ID: 23504258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A feast of reviews about brain and pituitary tumor pathology.
    Louis DN
    Brain Tumor Pathol; 2018 Apr; 35(2):49-50. PubMed ID: 29666968
    [No Abstract]   [Full Text] [Related]  

  • 16. Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification.
    Komori T
    Brain Tumor Pathol; 2020 Jan; 37(1):1-4. PubMed ID: 32060660
    [No Abstract]   [Full Text] [Related]  

  • 17. [IDH mutation on glioma].
    Mukasa A
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
    [No Abstract]   [Full Text] [Related]  

  • 18. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma IDH1 mutation patterns off the beaten track.
    Pusch S; Sahm F; Meyer J; Mittelbronn M; Hartmann C; von Deimling A
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):428-30. PubMed ID: 20874727
    [No Abstract]   [Full Text] [Related]  

  • 20. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
    Lu VM; McDonald KL
    CNS Oncol; 2018 Jan; 7(1):41-50. PubMed ID: 29303363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.